Scientific production of the research group in 2022
König M, Torgauten HM, Tran TT, Holmøy T, Vaage JT, Lund-Johansen F, Nygaard GO (2022)
Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
JAMA Neurol, 79 (3), 307-309
DOI 10.1001/jamaneurol.2021.5109, PubMed 35072702
Nygaard GO, Torgauten H, Skattebøl L, Høgestøl EA, Sowa P, Myhr KM, Torkildsen Ø, Celius EG (2022)
Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis
Mult Scler Relat Disord, 62, 103812
DOI 10.1016/j.msard.2022.103812, PubMed 35462167
Riise J, Meyer S, Blaas I, Chopra A, Tran TT, Delic-Sarac M, Hestdalen ML, Brodin E, Rustad EH, Dai KZ, Vaage JT, Nissen-Meyer LSH, Sund F, Wader KF, Bjornevik AT, Meyer PA, Nygaard GO, König M, Smeland S, Lund-Johansen F, Olweus J, Kolstad A (2022)
Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination
Br J Haematol, 197 (6), 697-708
DOI 10.1111/bjh.18149, PubMed 35254660